In a landmark decision for cancer care in England, the NHS has significantly broadened access to a life-extending prostate cancer treatment, offering new hope to thousands of men.
Expanded Eligibility for Vital Treatment
NHS England confirmed on Friday 16 January 2026 that it has expanded the eligibility criteria for the hormone therapy drug abiraterone. Previously, this treatment was reserved for patients whose prostate cancer had already spread, or metastasised.
Now, men diagnosed with high-risk prostate cancer that has not yet metastasised will also qualify for the drug on the health service. This pivotal change is expected to benefit a vast number of patients across the country.
Experts Hail 'Momentous Victory'
The medical community and leading charities have warmly welcomed the NHS's move. Professor Nick James from the Institute of Cancer Research (ICR) stated that the expansion is "really good news for men in England".
Amy Rylance, assistant director of health improvement at Prostate Cancer UK, celebrated the decision, calling it a "momentous, life-saving victory for the thousands of men" who will now be able to access the treatment. The drug works by inhibiting testosterone production, which fuels the growth of prostate cancer cells, thereby helping to extend lives.
A Turning Point in Patient Care
This policy shift represents a major step forward in the management of prostate cancer within the UK's public health system. By offering abiraterone earlier in the treatment pathway, the NHS aims to improve outcomes for those with aggressive forms of the disease before they spread.
The announcement follows the recent revelation by David Cameron about his own prostate cancer diagnosis, which helped to heighten public awareness of the condition. The expanded access underscores a continued commitment to enhancing oncology services and providing cutting-edge treatments to NHS patients.
